Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial.
Daniel J GeorgeDavid R SpigelLucio N GordanSamith T KochuparambilAna M MolinaJeff YorioArash Rezazadeh KalebastyHeidi McKeanNishan TchekmedyianScott S TykodiJoshua ZhangMargarita AskelsonJennifer L JohansenThomas E HutsonPublished in: BMJ open (2022)
NCT02982954.